Skip to main content
Erschienen in:

08.12.2020 | original article

Association of digoxin therapy with case fatality rate in acute pulmonary embolism

verfasst von: Mehmet Baran Karataş, M.D., Nizamettin Selçuk Yelgeç, M.D., Yiğit Çanga, M.D., Ahmet Zengin, M.D., Ayşe Emre, M.D.

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 21-22/2021

Einloggen, um Zugang zu erhalten

Summary

Objective

Despite wide usage of digoxin for various diseases in cardiology practice, its benefit is controversial and moreover it had been associated with unfavorable outcomes in some previous studies. The aim of this present study was to demonstrate whether digoxin usage was related with worse outcomes or not in patients with acute pulmonary embolisms.

Methods

A total number of 1215 patients retrospectively enrolled for the study. Basic demographic features, pulmonary embolism severity index (PESI) scores, laboratory parameters and medications of patients who had been diagnosed with acute pulmonary embolism were recorded. Short (30 days) and long-term mortality were reported as the clinical outcomes.

Results

Total mortality was 15.4% in the study population and 78 of these subjects died within the first 30 days. The frequency of digoxin treatment was 8% and most of these patients were prior users. According to the binary logistic regression analyses the PESI score, right ventricle (RV) diastolic diameter, systolic pulmonary arterial pressure (sPAP), brain natriuretic peptide (BNP), troponin and digoxin therapy (odds ratio, OR: 2.82 95% confidence interval, CI: 1.39–8.31, P = 0.03) were found as independent predictors of short-term mortality. Beside these findings; sPAP, PESI score, RV diastolic diameter and digoxin therapy (hazard ratio, HR: 2.11 95%CI: 1.22–7.31, P = 0.03) were determined as independent predictors of long-term mortality in Cox regression analyses. In subgroup analysis, we determined significantly greater increase in short-term mortality with use of digoxin among patients who had chronic renal disease, among patients under thrombolytic therapy and under high dosage of digoxin therapy and among female patients.

Conclusion

Digoxin has been used extensively for decades in the treatment of heart failure and arrhythmias despite some controversies over its benefit. For the first time in the literature, we have demonstrated independent association of digoxin therapy with short-term and long-term mortality in patients with acute pulmonary embolism.
Literatur
1.
Zurück zum Zitat Ziff OJ, Lane DA, Samra M, et al. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ. 2015;351:h4451.CrossRef Ziff OJ, Lane DA, Samra M, et al. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ. 2015;351:h4451.CrossRef
2.
Zurück zum Zitat Vamos M, Erath JW, Hohnloser SH. Digoxin-associated mortality: a systematic review and meta-analysis of the literature. Eur Heart J. 2015;36(28):1831–8.CrossRef Vamos M, Erath JW, Hohnloser SH. Digoxin-associated mortality: a systematic review and meta-analysis of the literature. Eur Heart J. 2015;36(28):1831–8.CrossRef
3.
Zurück zum Zitat Lopes RD, Rordorf R, De Ferrari GM, et al. Digoxin and mortality in patients with atrial fibrillation. J Am Coll Cardiol. 2018;71(10):1063–74.CrossRef Lopes RD, Rordorf R, De Ferrari GM, et al. Digoxin and mortality in patients with atrial fibrillation. J Am Coll Cardiol. 2018;71(10):1063–74.CrossRef
4.
Zurück zum Zitat Metawee M, Charnigo R, Morales G, et al. Digoxin and short term mortality after acute STEMI: results from the MAGIC trial. Int J Cardiol. 2016;218:176–80.CrossRef Metawee M, Charnigo R, Morales G, et al. Digoxin and short term mortality after acute STEMI: results from the MAGIC trial. Int J Cardiol. 2016;218:176–80.CrossRef
5.
Zurück zum Zitat Chan KE, Lazarus JM, Hakim RM. Digoxin associates with mortality in ESRD. J Am Soc Nephrol. 2010;21(9):1550–9.CrossRef Chan KE, Lazarus JM, Hakim RM. Digoxin associates with mortality in ESRD. J Am Soc Nephrol. 2010;21(9):1550–9.CrossRef
6.
Zurück zum Zitat Allen LA, Fonarow GC, Simon DN, et al. Digoxin use and subsequent outcomes among patients in a contemporary atrial fibrillation cohort. J Am Coll Cardiol. 2015;65(25):2691–8.CrossRef Allen LA, Fonarow GC, Simon DN, et al. Digoxin use and subsequent outcomes among patients in a contemporary atrial fibrillation cohort. J Am Coll Cardiol. 2015;65(25):2691–8.CrossRef
7.
Zurück zum Zitat Washam JB, Stevens SR, Lokhnygina Y, et al. Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Lancet. 2015;385(9985):2363–70.CrossRef Washam JB, Stevens SR, Lokhnygina Y, et al. Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Lancet. 2015;385(9985):2363–70.CrossRef
8.
Zurück zum Zitat Whitbeck MG, Charnigo RJ, Khairy P, et al. Increased mortality among patients taking digoxin—analysis from the AFFIRM study. Eur Heart J. 2013;34(20):1481–8.CrossRef Whitbeck MG, Charnigo RJ, Khairy P, et al. Increased mortality among patients taking digoxin—analysis from the AFFIRM study. Eur Heart J. 2013;34(20):1481–8.CrossRef
9.
Zurück zum Zitat Turakhia MP, Santangeli P, Winkelmayer WC, et al. Increased mortality associated with digoxin in contemporary patients with atrial fibrillation: findings from the TREAT-AF study. J Am Coll Cardiol. 2014;64(7):660–8.CrossRef Turakhia MP, Santangeli P, Winkelmayer WC, et al. Increased mortality associated with digoxin in contemporary patients with atrial fibrillation: findings from the TREAT-AF study. J Am Coll Cardiol. 2014;64(7):660–8.CrossRef
10.
Zurück zum Zitat Eisen A, Ruff CT, Braunwald E, et al. Digoxin use and subsequent clinical outcomes in patients with atrial fibrillation with or without heart failure in the ENGAGE AF-TIMI 48 trial. J Am Heart Assoc. 2017;6(7):e6035.CrossRef Eisen A, Ruff CT, Braunwald E, et al. Digoxin use and subsequent clinical outcomes in patients with atrial fibrillation with or without heart failure in the ENGAGE AF-TIMI 48 trial. J Am Heart Assoc. 2017;6(7):e6035.CrossRef
11.
Zurück zum Zitat Heit JA. The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol. 2008;28(3):370–2.CrossRef Heit JA. The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol. 2008;28(3):370–2.CrossRef
12.
Zurück zum Zitat Oh JK, Seward JB, Tajik AJ. The echo manual. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2009. pp. 401–15. Oh JK, Seward JB, Tajik AJ. The echo manual. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2009. pp. 401–15.
13.
14.
Zurück zum Zitat The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336(8):525–33.CrossRef The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336(8):525–33.CrossRef
15.
Zurück zum Zitat Gheorghiade M, Braunwald E. Reconsidering the role for digoxin in the management of acute heart failure syndromes. JAMA. 2009;302(19):2146–7.CrossRef Gheorghiade M, Braunwald E. Reconsidering the role for digoxin in the management of acute heart failure syndromes. JAMA. 2009;302(19):2146–7.CrossRef
16.
Zurück zum Zitat Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med. 2002;347(18):1403–11.CrossRef Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med. 2002;347(18):1403–11.CrossRef
17.
Zurück zum Zitat Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed. J Am Coll Cardiol. 2009;53(15):e1–e90.CrossRef Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed. J Am Coll Cardiol. 2009;53(15):e1–e90.CrossRef
18.
Zurück zum Zitat Leor J, Goldbourt U, Rabinowitz B, et al. Digoxin and increased mortality among patients recovering from acute myocardial infarction: importance of digoxin dose. Cardiovasc Drugs Ther. 1995;9(5):723–9.CrossRef Leor J, Goldbourt U, Rabinowitz B, et al. Digoxin and increased mortality among patients recovering from acute myocardial infarction: importance of digoxin dose. Cardiovasc Drugs Ther. 1995;9(5):723–9.CrossRef
19.
Zurück zum Zitat Alajaji W, Baydoun A, Al-Kindi SG, et al. Digoxin therapy for cor pulmonale: a systematic review. Int J Cardiol. 2016;223:320–4.CrossRef Alajaji W, Baydoun A, Al-Kindi SG, et al. Digoxin therapy for cor pulmonale: a systematic review. Int J Cardiol. 2016;223:320–4.CrossRef
20.
Zurück zum Zitat Rich S, Seidlitz M, Dodin E, et al. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest. 1998;114(3):787–92.CrossRef Rich S, Seidlitz M, Dodin E, et al. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest. 1998;114(3):787–92.CrossRef
21.
Zurück zum Zitat Mina GS, Acharya M, Shepherd T, et al. Digoxin is associated with increased shock events and electrical storms in patients with implantable cardioverter defibrillators. J Cardiovasc Pharmacol Ther. 2018;23(2):142–8.CrossRef Mina GS, Acharya M, Shepherd T, et al. Digoxin is associated with increased shock events and electrical storms in patients with implantable cardioverter defibrillators. J Cardiovasc Pharmacol Ther. 2018;23(2):142–8.CrossRef
22.
Zurück zum Zitat Virgadamo S, Charnigo R, Darrat Y, et al. Digoxin: a systematic review in atrial fibrillation, congestive heart failure and post myocardial infarction. World J Cardiol. 2015;7(11):808.CrossRef Virgadamo S, Charnigo R, Darrat Y, et al. Digoxin: a systematic review in atrial fibrillation, congestive heart failure and post myocardial infarction. World J Cardiol. 2015;7(11):808.CrossRef
23.
Zurück zum Zitat Furberg CD, Vittinghoff E, Davidson M, et al. Subgroup interactions in the heart and estrogen/progestin replacement study: lessons learned. Circulation. 2002;105(8):917–22.CrossRef Furberg CD, Vittinghoff E, Davidson M, et al. Subgroup interactions in the heart and estrogen/progestin replacement study: lessons learned. Circulation. 2002;105(8):917–22.CrossRef
24.
Zurück zum Zitat Aebi S, Schnider TW, Los G, et al. A phase II/pharmacokinetic trial of high-dose progesterone in combination with paclitaxel. Cancer Chemother Pharmacol. 1999;44(3):259–65.CrossRef Aebi S, Schnider TW, Los G, et al. A phase II/pharmacokinetic trial of high-dose progesterone in combination with paclitaxel. Cancer Chemother Pharmacol. 1999;44(3):259–65.CrossRef
Metadaten
Titel
Association of digoxin therapy with case fatality rate in acute pulmonary embolism
verfasst von
Mehmet Baran Karataş, M.D.
Nizamettin Selçuk Yelgeç, M.D.
Yiğit Çanga, M.D.
Ahmet Zengin, M.D.
Ayşe Emre, M.D.
Publikationsdatum
08.12.2020
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 21-22/2021
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-020-01773-z